In this free webinar, learn about current therapeutic vaccine research focusing on cancer and infectious disease indications. Attendees will gain insights into the unique requirements and best...

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced the Company will...

– New data from the HuMAIN study, which met the primary endpoint of weight loss and several efficacy and pharmacodynamic secondary endpoints, will be presented in a Late Breaking Clinical...

Data recently presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer Treatment with Annamycin results in statistically significant...

Aulisa® Medical USA, Inc., a Palo Alto, CA-based pioneer in FDA-cleared wearable, wireless, app-enabled continuous vital sign monitoring and remote patient monitoring technology with alarm...

Rigorous evaluation certifies the superior quality of health information exchange and the highest standards of privacy and security. ROCKVILLE, Md., Sept. 23, 2024 /PRNewswire/ -- Secure Exchange...

̶ Data From Narcolepsy Type 2 Cohort of ALKS 2680 Phase 1b Study to be Presented in Oral Presentation ̶ ̶ Data From Idiopathic Hypersomnia Cohort of ALKS 2680 Phase 1b Study Accepted for Poster...

Quanta Services, Inc. (NYSE: PWR) announced today that company management will participate in the Wolfe Research Utilities, Midstream & Clean Energy Conference 2024. Duke Austin, Chief Executive...

Phase 2 company-sponsored and IST neoadjuvant uveal melanoma (UM) clinical data update in 49 evaluable patients, demonstrates ~49% of patients with >30% tumor shrinkage by product of diameters,...

On September 14, 2024, BioCity presented interim clinical results on the safety and efficacy of its first-in-class antibody-drug conjugate (ADC) BC3195 targeting CDH3 (P-Cadherin) in a Phase I...